DUBLIN, Nov. 21, 2022 /PRNewswire/ — The “Digital Marketing Trends in Severe Asthma” report has been added to ResearchAndMarkets.com’s offering.
Sanofi/Regeneron’s Dupixent.com achieved the highest traffic across branded severe asthma patient sites in the US from July 2021 to June 2022, with about 7,800,000 visits, followed by Novartis’ Xolair.com, and GSK’s Nucala.com.
The highest proportion of traffic to these sites originated from direct sources, followed by organic searches. Amgen/AstraZeneca’s Tezspire.com had the highest amount of direct traffic (83%), while remaining brands, Dupixent, Cinqair, Nucala, and Xolair, had levels between 52-66%.
For patient branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $4.2 million, followed by GSK’s Nucala.com at approximately $900,000. Dupixent.com was supported by the most paid keywords at approximately 10,650 keywords, followed by Tezspire.com at about 5,800 keywords.
For branded HCP sites in the US, Sanofi/Regeneron’s Dupixenthcp.com had the highest number of visits at approximately 775,000 total visits, followed by AstraZeneca’s Fasenrahcp.com, and GSK’s Nucalahcp.com. The highest proportion of traffic to these sites originated from direct, followed by organic and referral sources.
Teva’s Cinqairhcp.com had the highest proportion of traffic from direct searches (81%). Sanofi/Regeneron spent the most on DDA for Dupixenthcp.com at approximately $51,400, followed by Amgen/AstraZeneca’s Tezspirehcp.com at approximately $17,100.
Between July 2021 and June 2022, the top 20 social media asthma posts by interaction from pharma were from Sanofi’s Facebook accounts, Genentech’s Instagram, Regeneron’s Instagram, Fasenra’s Facebook, and GSK’s Instagram. AstraZeneca’s Vik Asthma is the only severe asthma app detected from pharma in the US, with an estimated 30,700 downloads in 2021.
Most branded websites in EUCAN are patient-directed and few generated notable traffic between July 2021 and June 2022. Sanofi/Regeneron’s Dupixentmyway.co.uk and Dupixent.co.uk achieved the highest traffic, with about 20,200 and 3,400 visits, respectively.
Between July 2021 and June 2022, eight of the top 20 social media asthma posts by interaction in EUCAN from pharma were from AstraZeneca Espana’s Instagram account. No asthma mobile apps were detected from pharma in EUCAN.
Scope
This report assesses key digital marketing metrics of pharma assets in severe asthma, including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts.
Metrics include website traffic volume, engagement, and source, digital display advertising (DDA), paid search engine optimization (SEO), mobile app downloads, and social media post interaction.
Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).
Reasons to Buy
Understand the digital marketing competitive landscape in severe asthma, with a view of leading patient and HCP branded assets across different regions.
See what tactics pharma companies are using to drive traffic to their severe asthma branded assets for patient and HCPs, such as DDA and paid SEO.
Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches.
Compare top branded assets for patients by how they address and support different patient needs.
See what pharma social media accounts in severe asthma are the most active and achieving the most engagement.
See leading mobile app offerings in severe asthma from pharma across different regions.
Key Topics Covered:
Executive Summary
US Patient Branded Websites
US HCP Branded Websites
US Digital Display Advertising and Search Engine Optimization
US Mobile Apps and Social Media
EUCAN Branded Websites
EUCAN Mobile Apps and Social Media
Appendix
Companies Mentioned
Sanofi
Regeneron
Genentech
Novartis
GSK
AstraZeneca
Amgen
Teva
For more information about this report visit https://www.researchandmarkets.com/r/dzcu6v
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/severe-asthma-digital-marketing-trends-report-2022-featuring-sanofi-regeneron-genentech-novartis-gsk-astrazeneca-amgen–teva-301683667.html
SOURCE Research and Markets
The airbase, used by Russian planes targeting Ukraine, is hit for the second time this month.
Take a look at this list of stock market holidays in 2022 to find out whether the market will be open on days like Labor Day, Black Friday, Christmas Eve and more.
In this article, we discuss 10 stocks that Jim Cramer is bearish on. Stocks plummeted for a fourth consistent trading week on December 19, crushed by rising recession fears. However, CNBC’s Jim Cramer noted that there could be a buying opportunity in the equity markets ahead of a potential rally. On December 19, Cramer told investors: […]
Will there be a new beginning?
Three major headwinds have been combining to buffet the markets – persistently high inflation, the Fed’s rising interest rates in its ongoing battle to tame it, and the increasing worries that a recession is around the corner. In such an unpredictable market environment, investors need to find some clear and reliable sign to indicate just which stocks are the most attractive choices to weather the volatile conditions. One of the clearest such signals comes from the corporate insiders, company of
Many, if not most, investors, have seen their portfolios sink as well in 2022 — but not Warren Buffett. Most of Buffett's personal fortune is invested in Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B). Although there are still a few days left in December, Berkshire looks to be in great shape to deliver a positive, albeit small, annual gain.
It has been a rough year for semiconductor stocks, but all may not be lost. After all, semiconductors power all of today's big technology applications, from artificial intelligence, to the Internet of Things, to the Metaverse and electric vehicles. While somewhat cyclical, semiconductor stocks are usually generally quite profitable, and their stocks are less expensive than the high-flying software sector.
Undoubtedly, electric vehicles (EVs) will become the norm over the next couple of decades, ending more than 100 years of internal combustion engine automobile dominance. Statista estimates that sales will grow at a compound annual rate of nearly 17% through 2027, going from $389 billion in 2022 to $847 billion. Tesla is one of the most successful investments of the last 10 years, returning an eye-popping 5,700%.
The ailing market rally is still fighting. Celsius, Shift4Payments lead growth stocks to watch. Tesla Shanghai production has been suspended.
Until the 1980s, most of America used pensions to plan for retirement. These defined-benefit plans offered by employers saved a fund on behalf of their workers and calculated each employee's retirement benefits individually. This put all the responsibility and associated risks … Continue reading → The post Is a 401(k) Worth It? appeared first on SmartAsset Blog.
Biotech company Moderna (NASDAQ: MRNA) has been southbound for most of the year, but the vaccine maker seems to be ending 2022 on a high note. As is usually the case with biotechs, Moderna had good news from the clinic to thank for that impressive one-day rally (more on that later). Are Moderna's shares still worth buying right now?
The slowdown in inflation is underway, but will take a bigger slowdown in the economy to reach the Fed's objective.
Healthcare stocks with dividends can be a good place to park funds during inflationary periods. Medical Properties Trust (NYSE: MPW), Sanofi (NASDAQ: SNY), and Medtronic (NYSE: MDT) all have dividends yielding 2.5% or more with a history of consistent increases to reward long-term investors. Medical Properties Trust is one of the world's largest owners of hospitals with 434 in total that it leases across 30 states and 10 countries.
Lizzo concerts and subsidized butlers have been among the perks offered in the push for a return to in-person working this year.
Shares of the Magic Kingdom have recently sunk below where they were in early 2020 (when theme parks were completely closed down) and sit at similar levels as in late 2014 (after Disney acquired Lucasfilm but before new Star Wars movies began coming out). Returning CEO Bob Iger is taking back the reins of a pumpkin past midnight. Surely it's time to sell Disney, right?
Palantir (NYSE: PLTR) and DigitalOcean (NYSE: DOCN) have fallen 84% and 80% from their respective all-time highs and may never return to those highs. What do Palantir and DigitalOcean do? Both companies focus on the direction the business world is moving in, with Palantir having a robust artificial-intelligence-fueled data analysis platform and DigitalOcean providing cloud computing infrastructure to small businesses and individuals.
Some of the biggest names in the world had a lousy year which makes them perfect additions to your portfolio.
Years ago, investors observed that a phenomenon dubbed the Santa Claus rally often occurred during the year-end holidays. Three Motley Fool contributors identified stocks they think could soar in a Santa Claus rally. Here's why they picked Gilead Sciences (NASDAQ: GILD), NovoCure (NASDAQ: NVCR), and Pfizer (NYSE: PFE).
If $1 million was once the consensus target for retirement savings in the U.S., that appears to be changing. A recent Schwab Retirement Plan Services survey found that 401(k) plan participants across the country now believe they must save $1.9 … Continue reading → The post 401(k) Plan Participants Say They Need to Save This Much to Retire appeared first on SmartAsset Blog.
What a horrible year: Rivian would be tempted to say. Everything went wrong on the stock market for the young electric vehicle manufacturer, considered one of Tesla's most serious rivals. At the time of writing, Rivian's stock is trading around $19.14.
